PT  - JOURNAL ARTICLE
AU  - van Leusden, F.J.
AU  - Staal, D.P.
AU  - van Thor, M.C.J.
AU  - Rensing, B.J.M.W.
AU  - van Kuijk, J.P.
AU  - Mulder, B.J.M.
AU  - van den Heuvel, D.
AU  - Boerman, S.
AU  - Boomars, K.A.
AU  - Peper, J.
AU  - Mager, J.J.
AU  - Post, M.C.
TI  - Safety of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: role of the standardized definition of complications
AID  - 10.1101/2024.04.19.24306107
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.19.24306107
4099  - http://medrxiv.org/content/early/2024/04/21/2024.04.19.24306107.short
4100  - http://medrxiv.org/content/early/2024/04/21/2024.04.19.24306107.full
AB  - Literature reports high complication rates in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who undergo balloon pulmonary angioplasty (BPA), especially in patients with poor pulmonary hemodynamics. Here we describe complications of BPA based on the new definitions.All patients with CTEPH who completed BPA treatment before September 15th, 2023, were selected from the CTEPH database. Peri-procedural complications were collected and classified according to the 2023 consensus paper on BPA treatment. Complications were analyzed in subgroups of patients with pulmonary vascular resistance (PVR) ≤ or > 6.6 WU and mean pulmonary artery pressure (mPAP) ≤ or > 45 mmHg at first BPA.In this analysis, 87 patients (63% women; mean age 61.1±14.0 years; 62% on dual PH targeted medical therapy) underwent 426 (mean 4.9±1.6 per patient) BPAs. Only non-severe complications occurred in 14% of BPA treatments; in 47% of the patients; 31% patients had a thoracic complication. The thoracic complications were mild (71%) or moderate (29%). Patients with a PVR >6.6 WU (n=8) underwent more BPA treatments (6.6±1.5 versus 4.6±1.5, p=0.002), had more complications (88% versus 41% of patients, p=0.020), and more thoracic complications (17% vs 7% of BPAs, p=0.013) than patients with PVR ≤6.6 WU. Patients with mPAP >45 mmHg (n=13) also had more BPA-treatments (6.5±1.7 versus 4.6±1.4, p<0.001), more complications (77% versus 44% of patients, p=0.027) and more thoracic complications (14% versus 8% of BPAs, p=0.039) than patients with mPAP ≤45 mmHg.Complications occurred in 14% of BPAs and were mostly mild. Patients with severe pulmonary hemodynamics suffered more (thoracic) complications.What is known?BPA is an effective treatment in improving pulmonary hemodynamics in patients with CTEPH.BPAs are associated with a high complication rate.In 2023 a consensus statement was published concerning the definition of complications of BPAs.Patients with poor pulmonary hemodynamics may be more susceptible to suffer from complications.What does this study add?For the first time, complications are categorized according to the consensus statement on BPA treatments in patients with CTEPH.Thoracic complication rates in patients with severe pulmonary hemodynamics are significantly higher compared to complication rates in patients with lower pulmonary hemodynamic values.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research project was supported by an unrestricted research grant by Janssen-Cilag B.V.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the local ethical committee of the hospital (MEC-U, Z18.040).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, D.P. Staal. The data are not publicly available due to privacy restrictions.BPABalloon Pulmonary AngioplastyCOCardiac OutputCTEDChronic Thromboembolic DiseaseCTEPHChronic Thromboembolic Pulmonary HypertensionERAEndothelin Receptor AntagonistESCEuropean Society of CardiologyIQRInterquartile RangeMDTMulti-Disciplinary TeammPAPmean Pulmonary Arterial PressuremRAPmean Right Atrial PressureNTproBNPN-terminal prohormone of Brain Natriuretic PeptidePAWPPulmonary Artery Wedge PressurePDE5Phosphodiesterase-5PEAPulmonary EndarterectomyPHPulmonary HypertensionPVRPulmonary Vascular ResistanceRHCRight Heart CatheterizationSDStandard DeviationWHO FCWorld Health Organization functional classWUWoods Units6MWD6-minute walking distance95CI95% Confidence Interval